| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers B > Headlines for Biocompatibles International plc > News item |
SciClone acquires rights in China to Biocompatibles' cancer-treatment device
By E. Janene Geiss
Philadelphia, June 9 - SciClone Pharmaceuticals, Inc. said Friday that it has entered into a three-year agreement with Biocompatibles International plc, granting SciClone exclusive rights to market Biocompatibles' DC Bead chemotherapy-releasing device within China, particularly for the minimally invasive treatment of malignant hypervascular tumors such as primary liver cancer, hepatocellular carcinoma.
Liver cancer is one of the most prevalent and deadly forms of cancer in China accounting for more than 300,000 deaths each year, according to a company news release.
The DC Bead is designed to be used in trans-arterial chemoembolization procedures to embolize a tumor and deliver the chemotherapeutic agent, doxorubicin, to the tumor site in a targeted and consistent controlled-release manner.
Potential advantages include increasing the exposure of the tumor to the drug and reducing drug-related toxicity by minimizing systemic exposure, officials said.
Under this agreement, Biocompatibles said it will manufacture the DC Bead in the United Kingdom and supply the product to SciClone to market in China.
The agreement can be renewed three years post regulatory approval in China.
A regulatory submission for approval in China is planned during 2006, officials said. The DC Bead is approved in Europe for use in the treatment of malignant hypervascularized tumors.
"The DC Bead is a natural fit for us given our sales and marketing operation's experience in the area of liver disease in China," Friedhelm Blobel, president and chief executive officer of SciClone, said in the release.
Biocompatibles is a Surrey, England, medical technology company focused on drug device combination products for use in oncology and cardiology.
SciClone is a San Mateo, Calif., biopharmaceutical company.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.